Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease
BACKGROUND: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown.
OBJECTIVE: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks.
METHODS: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment.
RESULTS: Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral n = 14, bilateral n = 5, associated with transverse myelitis (TM), n = 1), followed by acute disseminated encephalomyelitis (ADEM) (n = 8), multifocal (n = 7), TM (n = 3), brainstem (n = 1), and other encephalitis (n = 1). A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation (p < 0.0001 for both outcome measures).
CONCLUSION: IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Multiple sclerosis (Houndmills, Basingstoke, England) - 29(2023), 9 vom: 01. Aug., Seite 1080-1089 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lotan, Itay [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.08.2023 Date Revised 10.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/13524585231184738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359321399 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359321399 | ||
| 003 | DE-627 | ||
| 005 | 20231226080625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/13524585231184738 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359321399 | ||
| 035 | |a (NLM)37431144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lotan, Itay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.08.2023 | ||
| 500 | |a Date Revised 10.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown | ||
| 520 | |a OBJECTIVE: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks | ||
| 520 | |a METHODS: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment | ||
| 520 | |a RESULTS: Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral n = 14, bilateral n = 5, associated with transverse myelitis (TM), n = 1), followed by acute disseminated encephalomyelitis (ADEM) (n = 8), multifocal (n = 7), TM (n = 3), brainstem (n = 1), and other encephalitis (n = 1). A significant improvement in both the EDSS and VA measures was observed at follow-up compared to the time of IVIG treatment initiation (p < 0.0001 for both outcome measures) | ||
| 520 | |a CONCLUSION: IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a IVIG | |
| 650 | 4 | |a MOGAD | |
| 650 | 4 | |a acute treatment | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Chen, John J |e verfasserin |4 aut | |
| 700 | 1 | |a Hacohen, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Mannan, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Mariotto, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Huda, Saif |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbons, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Wilf-Yarkoni, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmann, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Stiebel-Kalish, Hadas |e verfasserin |4 aut | |
| 700 | 1 | |a Pittock, Sean J |e verfasserin |4 aut | |
| 700 | 1 | |a Flanagan, Eoin P |e verfasserin |4 aut | |
| 700 | 1 | |a Molazadeh, Negar |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Salky, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Romanow, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Schindler, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Duchow, Ankelien Solveig |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Friedemann |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis (Houndmills, Basingstoke, England) |d 1997 |g 29(2023), 9 vom: 01. Aug., Seite 1080-1089 |w (DE-627)NLM09012992X |x 1477-0970 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:9 |g day:01 |g month:08 |g pages:1080-1089 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/13524585231184738 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 9 |b 01 |c 08 |h 1080-1089 | ||